Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : QRX003
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Preclinical
Sponsor : Quoin Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the terms of the agreement, AFT has exclusive rights to commercialize QRX003, a potential treatment for Netherton Syndrome in Australia and New Zealand, upon the receipt of regulatory approvals in both territories.
Product Name : QRX003
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
August 11, 2021
Lead Product(s) : QRX003
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Preclinical
Sponsor : Quoin Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Paracetamol,Ibuprofen
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Hikma Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Hikma gets rights for the sales, marketing and distribution of Combogesic® IV in the US. Combogesic® IV is a patented intravenous formulation developed as a line extension to Maxigesic tablets, used post-operatively in hospitals when patients cannot ta...
Product Name : Combogesic IV
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 28, 2021
Lead Product(s) : Paracetamol,Ibuprofen
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Hikma Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Sirolimus
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Timber Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Extension of agreement with AFT Pharmaceuticals grants Desitin Arzneimittel GmbH exclusive license and supply rights for TMB-002 in Europe.
Product Name : Pascomer
Product Type : Antibiotic
Upfront Cash : Undisclosed
March 17, 2021
Lead Product(s) : Sirolimus
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Timber Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement